Anatara Lifesciences Limited (ASX:ANR) Monthly Activities Report
Monthly Activities ReportMelbourne, July 28, 2021 AEST (ABN Newswire) - Anatara Lifesciences Limited (
ASX:ANR), a developer of evidence based solutions for gastrointestinal diseases in animals and humans, is pleased to provide this activities report for the quarter ending 30 June 2021 (Q4 FY21), along with the Company s Appendix 4C cash flow report.
Commenting on the quarter, CEO Steve Lydeamore said, Anatara is pleased to have made solid progress in obtaining the appropriate approval and grants for our human and animal health products over this period. We are at an exciting phase of Anatara s development, with two human clinical trials now imminent, and a number of pathways being pursued for the commercialisation of both the human and animal products.